You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Response criteria

Showing 26 - 50 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

ALK-positive Advanced NSCLC Trial in Worldwide (Brigatinib)

Active, not recruiting
Has Results
  • ALK-positive Advanced NSCLC
  • Orange, California
  • +79 more
Nov 15, 2022

DLBCL Trial in Belgium, France (Tafasitamab, Lenalidomide, Rituximab)

Recruiting
  • DLBCL
  • Brussels, Belgium
  • +14 more
Mar 3, 2022

Upadacitinib of Enthesitis Evaluated by Ultrasound in Psoriatic

Not yet recruiting
  • Psoriatic Arthritis
  • Madrid, Spain
    Instituto de Investigación Sanitaria Fundación Jiménez Díaz
Nov 25, 2023

Hepatocellular Carcinoma Trial in Worldwide (lenvatinib, pembrolizumab (200 mg))

Completed
Has Results
  • Hepatocellular Carcinoma
  • San Francisco, California
  • +25 more
Jan 13, 2023

Relapsed Refractory Multiple Myeloma Trial (REGN5458, Elotuzumab, Pomalidomide)

Not yet recruiting
  • Relapsed Refractory Multiple Myeloma
  • (no location specified)
Feb 6, 2023

Multiple Myeloma Trial (Continued treatment adapted to the response)

Completed
  • Multiple Myeloma
  • Continued treatment adapted to the response
  • (no location specified)
Jan 14, 2023

Brain Tumor Trial in Salt Lake City (Multi-tracer PET exams of [18F]FLT and [18F]Fluciclovine)

Recruiting
  • Brain Tumor
  • Multi-tracer PET exams of [18F]FLT and [18F]Fluciclovine
  • Salt Lake City, Utah
    Huntsman Cancer Institute
Oct 6, 2022

Squamous Cell Carcinoma Trial (MK-3475A)

Not yet recruiting
  • Squamous Cell Carcinoma
  • MK-3475A
  • (no location specified)
Sep 11, 2023

Pancreatic Tumors Trial in Shanghai (Utidelone injection in combination with gemcitabine)

Recruiting
  • Pancreatic Neoplasms
  • Utidelone injection in combination with gemcitabine
  • Shanghai, Shanghai, China
    Shanghai First People's Hospital
Mar 21, 2023

A Prospective Observational Study for Evaluating CGVHD

Completed
  • Chronic Graft-Versus-Host Disease
    • Alessandria, Italy
    • +26 more
    Nov 23, 2022

    Long-term Endogenous Androgen Priming in Bologna Criteria Poor

    Completed
    • Poor Ovarian Response
    • Androgen priming
    • Ho Chi Minh City, Vietnam
      Lan N Vuong
    Jul 2, 2019

    Peripheral T-cell Lymphoma Trial in Worldwide (Romidepsin + CHOP, CHOP)

    Completed
    • Peripheral T-cell Lymphoma
    • Antwerpen, Belgium
    • +130 more
    Jan 9, 2023

    Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Follicular Lymphoma Trial in Spokane, Salamanca (Zilovertamab vedotin,

    Recruiting
    • Chronic Lymphocytic Leukemia
    • +3 more
    • Spokane, Washington
    • +1 more
    Aug 12, 2022

    Breast Cancer Metastatic Trial in Spain (Irinotecan Hydrochloride)

    Recruiting
    • Breast Cancer Metastatic
    • Irinotecan Hydrochloride
    • Badalona, Spain
    • +19 more
    Jan 18, 2023

    DLBCL, DLBCL Trial in Worldwide (Zilovertamab vedotin, Rituximab, Gemcitabine)

    Recruiting
    • DLBCL
    • Diffuse Large B-Cell Lymphoma
    • Zilovertamab vedotin
    • +4 more
    • Whittier, California
    • +21 more
    Nov 30, 2022

    Fibromatosis Trial in Jacksonville (Triamcinolone Acetonide)

    Completed
    • Fibromatosis
    • Triamcinolone Acetonide
    • Jacksonville, Florida
      Mayo Clinic in Florida
    Aug 24, 2022

    Plasma Cell Myeloma Trial in Worldwide (Isatuximab SAR650984, Bortezomib, Lenalidomide)

    Active, not recruiting
    • Plasma Cell Myeloma
    • Isatuximab SAR650984
    • +3 more
    • Fort Myers, Florida
    • +103 more
    Nov 3, 2022

    Metastatic Cancer, Solid Tumor Trial in Worldwide (Sym021, Sym022, Sym023)

    Active, not recruiting
    • Metastatic Cancer
    • Solid Tumor
    • Aurora, Colorado
    • +17 more
    Sep 8, 2022

    Multiple Myeloma Trial in Worldwide (Carfilzomib 20 mg/m^2, Carfilzomib 70 mg/m^2, Dexamethasone 40 mg)

    Active, not recruiting
    • Multiple Myeloma
    • Carfilzomib 20 mg/m^2
    • +4 more
    • Gilbert, Arizona
    • +107 more
    Dec 20, 2022

    Leukemia, Lymphocytic, Chronic, B-Cell Trial in Austria (Bendamustine, Alemtuzumab)

    Completed
    • Leukemia, Lymphocytic, Chronic, B-Cell
    • Innsbruck, Tirol, Austria
    • +6 more
    Feb 15, 2022

    Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy, Pembrolizumab Trial in Beijing (Pembrolizumab, Cisplatin,

    Recruiting
    • Head and Neck Squamous Cell Carcinoma
    • +2 more
    • Beijing, Beijing, China
      Beijing Tongren Hospital
    Oct 26, 2023

    Metastatic Pancreatic Carcinoma Trial in Providence (CAR2 Anti-CEA CAR-T cells)

    Terminated
    • Metastatic Pancreatic Carcinoma
    • CAR2 Anti-CEA CAR-T cells
    • Providence, Rhode Island
      Roger Williams Medical Center
    Jan 12, 2023

    Coagulation Disorders on the Diagnosis and Prognosis of Sepsis

    Recruiting
    • Sepsis
    • Coagulation Disorder
    • Early general coagulation function (5 items of coagulation) and thromboelastogram monitoring
    • Shanghai, Shanghai, China
      Department of Emergency, Ruijin Hospital, Shanghai Jiao Tong Uni
    Aug 17, 2023

    Rheumatoid Arthritis Trial in Beijing (LNK01001 Dose A, LNK01001 Dose B, )

    Completed
    • Rheumatoid Arthritis
    • LNK01001 Dose A
    • +2 more
    • Beijing, China
      Peking Union Medical College Hospital
    Oct 24, 2023

    Real-life Current Standards of Care in Relapsed and/or

    Completed
    • Multiple Myeloma
    • No intervention
    • Tucson, Arizona
    • +85 more
    Dec 20, 2022